Gemcitabine

About

Therapy type: Chemotherapy

Therapy strategy: Antimetabolite

Mappings

NCI Thesaurus: Gemcitabine (ncit:C66876)

RxNorm: gemcitabine (rxcui:12574, omop:1314924)

SNOMED: Gemcitabine (sctid:386920008, omop:4305105)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
FDA (1) HER2-positive Invasive Breast Carcinoma Gemcitabine, Margetuximab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab
EMA (1) FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Pembrolizumab
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Gemcitabine, Pembrolizumab
EMA (1) HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
HSE (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Gemcitabine, Nivolumab
HSE (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine
HSE (1) CD20 + Diffuse Large B-Cell Lymphoma Gemcitabine, Oxaliplatin, Rituximab
HSE (1) CD20 + Non-Hodgkin Lymphoma Gemcitabine, Oxaliplatin, Rituximab